Raysearch Laboratories AB (publ) Interim report January 1 – June 30, 2016

“Revenues from RayStation® rose 100 percent to SEK 107.8 M (53.9) and prospects are favorable for the rest of the year.
The development of RayCare® is progressing as planned and we will demonstrate the system at the 2016 ASTRO radiation therapy conference in Boston at the end of September,” says Johan Löf, President and CEO of RaySearch.

SECOND QUARTER (APRIL - JUNE 2016)

• Net sales SEK 119.0 M (77.3), of which RayStation SEK 107.8 M (53.9)
• Profit after tax SEK 28.8 M (loss: 2.6) and earnings per share were SEK 0.84 (loss: 0.08)
• Operating profit SEK 37.5 M (loss: 2.1)
• Cash flow negative SEK 21.0 M (neg: 10.1)
• Order intake excl. service agreements SEK 129.1 M (72.0), of which RayStation SEK 120.8 M (55.3)
• Order backlog for RayStation was SEK 65.2 M (40.2) at the end of the period

HALF-YEAR (JANUARY - JUNE, 2016)

• Net sales SEK 214.4 M (165.1), of which RayStation SEK 188.6 M (116.6)
• Profit after tax SEK 46.6 M (22.4), and earnings per share SEK 1.36 (0.65)
• Operating profit SEK 60.8 M (31.0)
• Cash flow negative SEK 26.3 M (neg: 2.3)
• Order intake excluding service agreements SEK 211.0 M (158.3), of which RayStation SEK 193.4 M (124.4)

SIGNIFICANT EVENTS DURING THE SECOND QUARTER

• RaySearch has continued to secure more major orders from some of the world’s largest and most respected cancer clinics, including the University of California San Francisco and the Miami Cancer Institute in the US, a number of proton clinics in Japan, and the Holland Particle Therapy Centre in the Netherlands.

SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD

• Victoria Sörving, General Counsel, has decided to leave the company effective September.

ABOUT RAYSEARCH

RaySearch Laboratories is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch develops and markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company is also developing the next-generation oncology information system, RayCare, which comprises a new product area for RaySearch, and which will be launched in 2017. RaySearch’s software is currently used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since November 2003. More information about RaySearch is available at www.raysearchlabs.com.

FOR FURTHER INFORMATION, PLEASE CONTACT: